个人简介
Education:
Ph.D. Duke University, 1974
HONORS AND AWARDS
Phi Beta Kappa Honorary Society, 1968
Phi Kappa Phi Honorary Society, 1967
NIH Biomedical Science Research Award, 1972
Graduate School Research Award (Duke University), 1972
NIH Postdoctoral Fellowship, 1974
University of Kentucky Research Foundation Faculty Research Award, 1979
Awarded University of Kentucky Research Professorship, 1980 81
Appointed to Biophysics and Biophysical Chemistry Study Section A of the National Institutes of Health (NIGMS), Spring 1980 Meeting
Appointed to National Institute of Health Site Visit Study Section, Summer 1980
Invited Speaker, Gordon Research Conference on Magnetic Resonance in Biology and Medicine, 1980
Consultant, National Institute on Aging, NIH Site Visit, "Alzheimer's Disease Center," May, 1987
Consultant, National Heart, Lung and Blood Institute, NIH Site Visit, "Comprehensive Sickle Cell Disease Center," May, 1987
Special Faculty Grant, 1988 1990
Editorial Board Member, Journal of Membrane Science, 1989 present
Finalist, College of Arts and Sciences Distinguished Professorship, 1990, 1991
Dow Chemical Distinguished Lectureship, University of D etroit, 1995
The Honorable Order of Kentucky Colonels, 1995
Consultant, National Institute on Aging, NIH Reverse Site Visit on "β-Amyloid Program Project," 1996
Recipient, Distinguished University Scientist Award from the Kentucky Academy of Science, 1996
Consultant, National Science Foundation, Small Business Investigative Research Panel, 1996
Consultant, national Aeronautics and Space Administration, Shuttle Experiment Panel, 1997
Recipient, William B. Sturgill Award for Graduate Education, 1997
Recipient, Southern Chemist Award from the American Chemical Society, Memphis Section, 1997
Recipient, Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring, Presented by President Clinton in the White House , 1998.
Appointed as Senior Associate Editor, Journal of Alzheimer's Disease
Consultant, National Institute on Aging, NIH Site Visit on "Alzheimer's Disease PPG," 1998
Consultant, National Institute on Aging, NIH Site Visit on "Alzheimer's Disease PPG," 1999
Consultant, National Institute on Aging, NIH Site Visit on "Alzheimer's Disease PPG," 2000
Consultant, National Institute on Aging, NIH Site Visit on "Prion Disorders," 2002
Consultant, National Institute on Aging, NIH Site Visit on "Alzheimer's Disease," 2002
Consultant, National Institute on Aging, NIH Site Visit on "Alzheimer's Disease," 2003
Consultant, National Institute on Aging, NIH Site Visit on "Alzheimer's Disease," 2004
Consultant, National Institute on Aging, NIH Site Visit on "Alzheimer's Disease," 2005
Consultant, National Institute on Aging, NIH Site Visit on "Alzheimer's Disease," 2007
Recipient, Honorary Doctor of Science Degree, University of Maine, Commencement, 2002
Alumni Association Endowed Professor of Biological Chemistry, University of Kentucky, 2002-present
Member, Scientific Advisory Board for Neurobiology, National University of Singapore (One of only 4 international members)
Ad-hoc Member, Study Section on Conflict of Interest, NIGMS, NIH
Ad-hoc Member, Study Section on Synapses, NINDS, NIH
Recipient, Award for Most Outstanding PhD Committee Member for Prince of Songkla University, Thailand, 2007
International Member, Scientific Review Panel, Ministry of Education, for the Government of Singapore, 2006-present
Permanent Member, NIH Study Section on Neural Oxidative and Metabolic Death, 2008-2012
Invited Speaker, Gordon Research Conference on Oxygen Radicals, 2010
Recipient, Albert D. and Elizabeth H. Kirwan Memorial Prize for Excellence in Research, 2010
Member, Editorial Board, Neuroproteomics
Selected as a Fellow of the Society for Free Radical Biology and Medicine, 2012 (one of only 28 Fellows in the world).
Recipient, 2013 Discovery Award from the Society for Free Radical Biology and Medicine
2014: Editorial Board Member, Pharmacological Research
2014: Recipient, Alkmeon International Prize for Progress in Science, presented at the University of Rome, Tor Vergata in Rome, Italy
Member, Editorial Board, Frontiers in Pharmacology
2014: Recipient, Society for Free Radical Biology and Medicine Mentoring Excellence Award
2014: Elected Editorial Board Member, Free Radical Biology and Medicine
研究领域
The Butterfield laboratory studies free radical oxidative stress in aging and age-related neurodegenerative disorders, particularly Alzheimer's disease (AD). We discovered in AD brain that such oxidative stress is manifested by protein oxidation, lipid peroxidation, reactive oxygen species (ROS) production, mitochondrial dysfunction, and functional impairment of key transmembrane transport proteins, among many others. Our laboratory studies these and other aspects of oxidative stress in brain membranes using a variety of techniques, including immunochemical, metabolomic, and proteomics methods. Our group first described how oxidative stress associated with amyloid β-peptide, a 42-amino acid peptide deposited in AD brains, leads to neurotoxicity and how various antioxidants can modulate or prevent this oxidative stress and neuronal death. Insight into the molecular basis for and potential therapeutic interventions in aging and age-related neurodegenerative disorders is envisaged from our research.
Our laboratory pioneered the techniques of redox proteomics (see figure below) to identify oxidatively modified brain proteins in subjects with AD and, arguably, its earliest form, mild cognitive impairment (MCI). Proteins identified have provided new insights into molecular processes involved in mechanisms of neuronal death in and progression of AD.
Processes involved in redox proteomics, which is used to identify oxidatively modified brain proteins in Alzheimer's disease and other neurodegenerative disorders.
In a second area of research, the Butterfield laboratory discovered a mechanism for chemotherapy induced cognitive impairment (CICI), which lowers the quality of life for up to 70 percent of the currently 14 million cancer survivors in the USA. Diminished executive functioning, inability to multitask, and slowness in mental processing, called “chemobrain” by patients, often are complaints described by persons with CICI. Metabolic analyses using Seahorse technology and MS-based methods suggest mitochondrial dysfunction and apoptosis in brain following chemotherapy involving ROS associated chemotherapeutic agents, even though these agents do not cross the blood-brain barrier. We found an important inflammatory cytokine is elevated in plasma, and this harmful molecule does cross the BBB to initiate a series of harmful biochemical processes in brain. Highly innovative studies using a variety of biochemical and chemical techniques are shedding light on how to prevent CICI, with the strong possibility that the quality of life of cancer survivors will be enhanced.
近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
W.O. Opii, E. Head, D.M. Turner, W.M. Pierce, and D.A. Butterfield, "Proteomic Expression Analysis of Brain Proteins Form Dementia Free Nonagenarians: Relevance to Successful Aging and Alzheimer's Disease," manuscript in preparation (2015).
V. Vilchez, A.L. Castellanos, D.A.Butterfield, M. Mitov, L.I. Boral, C. Hoopes, R. Gedaly, and F. Marti, “Effects of Dual PI3K/mTOR Inhibitors in Differentiation and Expansion of Human Regulatory T Cells,” submitted (2015).
C.–H. Chen, W. Li, R. Sultana, M.-H. You, A. Kondo, K. Shahpasand, B.M. Kim, M. Luo, M. Nechama, Y.-M. Lin, Y. Yao, T.H. Lee, X.Z. Zhou, A.M. Swomley, D.A. Butterfield, Y. Zhang, and K.P. Lu, “ Pin 1 Cysteine-113 Oxidative Inhibits Its Catalytic Activity and Cellular Function in Alzheimer’s Dosease,” submitted (2015).
E. Barone, G. Cenini, F. Di Domenico, T. Noel, C. Wang, M. Perluigi , D.K. St. Clair, and D.A. Butterfield, “Basal Brain Oxidative and Nitrosative Stress Levels Are Finely Regulated by the Interplay between MnSOD and p53: Evidence from New Double-transgenic Mice,” submitted (2015).
J. Triplett, Z. Zhang, R. Sultana, J. Cai, J. Klein, H. Büeler, and D.A. Butterfield, "Quantitative Expression Proteomics and Phosphoproteomics Profiles of Brain from PINK1 Knockout Mice: Insights into Mechanisms of Familial Parkinson Disease," Journal of Neurochemistry, in press (2015).
A. Tramutola, J. Triplett, F. Di Domenico, D.M. Niedowicz, M.P. Murphy, R. Coccia, M. Perluigi, and D.A. Butterfield, “Alteration of mTOR Signaling During the Progression of Alzheimer Disease: Analysis of Human Brain from Three Different Clinical Stages,” Journal of Neurochemistry, in press (2015).
F. Di Domenico, G. Pupo, C. Mancuso, E. Barone, F. Paolini, A. Arena, C. Blarzino, F.A. Schmitt, E. Head, D.A. Butterfield, and M. Perluigi, “Bach1 Overexpression in Down Syndrome Correlates with the Alteration of the HO-1/BVR-A System: Insights for Transition to Alzheimer Disease,” Journal of Alzheimer’s Disease, in press (2015).
F. Di Domenico, M. Perluigi, and D.A. Butterfield, "Redox Proteomics in Human Biofluids: Sample Preparation, Separation, and Immunochemical Tagging for Analysis of Protein Oxidation” in Methods in Molecular Biology: Systems Biology of Alzheimer's Disease: Methods and Protocols, in press (2015).
T.T. Reed, Z.P. Sellers, and D.A. Butterfield, "Lipid Peroxidation in Age-related Neurodegenerative Disorders," in Lipid Oxidation in Health and Disease," C.M. Spickett and H.J. Forman, Eds., Taylor and Francis Publishers, Boca Raton, FL., in press (2015).
C. Mancuso, E. Head, E. Barone, M. Perluigi, P. Preziosi, and D.A. Butterfield, "The Potential Therapeutic Effects of Statins in Alzheimer's Disease," in Handbook of Neurotoxicity, R.M. Kostrzewa, Ed., Springer, New York, in press (2015).
F. Di Domenico, E. Barone, M. Perluigi, and D.A. Butterfield, “Strategy to Reduce Free Radical Species in Alzheimer’s Disease: An Update of Selected Antioxidants,” Expert Review of Neurotherapeutics 22, 1-22 (2014).
G. Cenini, A. Fiorini, R. Sultana, M. Perluigi, J. Cai, J.B. Klein, E. Head, and D.A. Butterfield, “An Investigation of the Molecular Mechanisms Engaged Before and After the Development of Alzheimer Disease Neuropathology in Down Syndrome: A Proteomics Approach,” Free Radical Biology & Medicine 76, 89-95 (2014).
D.A. Butterfield, F. Di Domenico, A.M. Swomley, E. Head, and M. Perluigi, “Redox Proteomics Analysis to Decipher the Neurobiology of Alzheimer-like Neurodegeneration: Overlaps in Down Syndrome and Alzheimer Disease Brain,” Biochemical Journal 463, 177-189 (2014).
S.S. Hardas, R. Sultana, W. Govind, M. Dan, P. Wu, E. Grulke, M. Tseng, J. Unrine, U. Graham, R. Yokel, and D.A. Butterfield, “Rat Hippocampal Responses Up to 90 Days after a Single Nanoceria Dose Extends a Hierarchical Oxidative Stress Model for Nanoparticle Toxicity,” Nanotoxicology 81, 155-166 (2014).
M.T. Tseng, Q. Fu, K. Lor, R. Fernandez-Botron, Z.B. Deng, U.M. Graham, D.A. Butterfield, E. Grulke, and R.A. Yokel, "Persistent Hepatic Structural Alterations Following Nanoceria Vascular Infusion in the Rat," Toxicologic Pathology 42, 984-996 (2014).
U.M. Graham, M.T. Tseng, J.B. Jasinski, R.A. Yokel, J.M. Unrine, B.H. Davis, A.K. Dozier, S.S. Hardas, R. Sultana, E.A. Grulke, and D.A. Butterfield, “In Vivo Processing of Ceria Nanoparticles Inside Liver: Impact on Free Radical Scavenging Activity and Oxidative Stress,” ChemPlusChem 79, 1083-1089 (2014).
D.A. Butterfield, “THE 2013 SFRBM DISCOVERY AWARD: Selected Discoveries from the Butterfield Laboratory of Oxidative Stress and Its Sequela in Brain in Cognitive Disorders Exemplified by Alzheimer Disease and Chemotherapy Induced Cognitive Impairment,” Free Radical Biology & Medicine 74, 157-174 (2014).
D. A. Butterfield, Fabio Di Domenico, and Eugenio Barone, "Elevated Risk of Type 2 Diabetes for Development of Alzheimer Disease: a Key Role for Oxidative Stress in Brain," Biochimica et Biophysica Acta - Molecular Basis of Disease 1842, 1693-1706 (2014).
F. Di Domenico, E. Head, D.A. Butterfield, and M. Perluigi, "Oxidative Stress and Proteostasis Network: Culprit and Casualty of Alzheimer’s-Like Neurodegeneration," Advances in Geriatrics 2014, 1-14 (2014).
S. Förster, A.S. Welleford, J.C. Triplett, R. Sultana, B. Schmitz, and D.A. Butterfield, “Increased O-GlcNAc Levels Correlate with Decreased O-GlcNAcase Levels in Alzheimer Disease Brain,” Biochimica et Biophysica Acta - Molecular Basis of Disease 1842, 1333-1339 (2014).
京公网安备 11010802027423号